Florentina Pascale1, Laurent Bedouet2, Mintham Baylatry3, Julien Namur4, Alexandre Laurent5. 1. ArchimMed, Jouy-en-Josas, France Interventional Imaging Center, Paris Hospitals and Healthcare Organisation, Jouy-en-Josas, France florentina.pascale@archimmed.com. 2. Occlugel, Jouy-en-Josas, France. 3. Saint Antoine Hospital, Assistance Publique Hopitaux de Paris (APHP), Paris, France. 4. ArchimMed, Jouy-en-Josas, France. 5. Interventional Imaging Center, Paris Hospitals and Healthcare Organisation, Jouy-en-Josas, France Faculty of Medicine, University Paris Diderot/Paris VII, Paris, France Department of Interventional Neuroradiology, Lariboisiere Hospital, Paris Hospitals and Healthcare Organisation, Paris, France.
Abstract
AIM: To compare the cytotoxic effects of 11 anticancer agents against VX2 and HepG2 cells in order to establish candidate drugs that can be tested preclinically on VX2 tumor model for transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: VX2 and HepG2 cells were incubated with different drug concentrations. The half-maximal inhibitory concentration (IC50) values were determined by total cell protein assay for anthracyclines, platins, irinotecan, mytomicin-C (MMC), 5-fluorouracil (5-FU) and antiangiogenics. RESULTS: IC50 values for VX2 and HepG2 were found close for doxorubicin (0.8 μM vs. 1.1 μM), MMC (13.9 μM vs. 8.7 μM), sunitinib (32.7 vs. 33.7 μM), sorafenib (10.3 vs. 8.9 μM), lapatinib (30 vs. 18.3 μM) and different for platins and irinotecan. Oxaliplatin was less active against VX2 than HepG2 (IC50=41 μM vs. 2.7 μM), cisplatin was more active against VX2 than HepG2 (IC50=8.0 μM vs. 15.9 μM), whereas carboplatin had a low toxicity against both cell lines (70.4 μM vs. 538.3 μM). The toxicity of 5-FU against VX2 and HepG2 was low (IC50=560.6 μM vs. 323.2 μM). Irinotecan was less active against VX2 vs. HepG2 (IC50=44.5 μM vs. 15.3 μM). Bevacizumab had no effect on either of the cell lines up to 6.7 μM. CONCLUSION: Drugs recommended for pre-clinical trials of TACE in the VX2 model are doxorubicin, sunitinib, sorafenib, MMC, lapatinib and 5-FU. Copyright
AIM: To compare the cytotoxic effects of 11 anticancer agents against VX2 and HepG2 cells in order to establish candidate drugs that can be tested preclinically on VX2 tumor model for transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: VX2 and HepG2 cells were incubated with different drug concentrations. The half-maximal inhibitory concentration (IC50) values were determined by total cell protein assay for anthracyclines, platins, irinotecan, mytomicin-C (MMC), 5-fluorouracil (5-FU) and antiangiogenics. RESULTS: IC50 values for VX2 and HepG2 were found close for doxorubicin (0.8 μM vs. 1.1 μM), MMC (13.9 μM vs. 8.7 μM), sunitinib (32.7 vs. 33.7 μM), sorafenib (10.3 vs. 8.9 μM), lapatinib (30 vs. 18.3 μM) and different for platins and irinotecan. Oxaliplatin was less active against VX2 than HepG2 (IC50=41 μM vs. 2.7 μM), cisplatin was more active against VX2 than HepG2 (IC50=8.0 μM vs. 15.9 μM), whereas carboplatin had a low toxicity against both cell lines (70.4 μM vs. 538.3 μM). The toxicity of 5-FU against VX2 and HepG2 was low (IC50=560.6 μM vs. 323.2 μM). Irinotecan was less active against VX2 vs. HepG2 (IC50=44.5 μM vs. 15.3 μM). Bevacizumab had no effect on either of the cell lines up to 6.7 μM. CONCLUSION: Drugs recommended for pre-clinical trials of TACE in the VX2 model are doxorubicin, sunitinib, sorafenib, MMC, lapatinib and 5-FU. Copyright
Authors: Gouri Nair; G N S Hema Sree; Ganesan Rajalekshmi Saraswathy; V Lakshmi Prasanna Marise; T P Krishna Murthy Journal: Med Oncol Date: 2021-10-23 Impact factor: 3.064
Authors: Ekaterina V Neborak; Altynay B Kaldybayeva; Lylia Bey; Aigul Y Malmakova; Anna S Tveritinova; Abdullah Hilal; Valentina K Yu; Maria V Ploskonos; Marina V Komarova; Enzo Agostinelli; Dmitry D Zhdanov Journal: Molecules Date: 2022-06-16 Impact factor: 4.927